Brad Millson is a Senior Principal within the Health Access and Outcomes consulting group at IQVIA.
Brad leads projects to deliver market access strategy and real-world evidence-based solutions for the pharmaceutical industry and its stakeholders. He joined the company in 2013, bringing his global expertise in pharmaceutical brand management, strong medical science training and strategic problem solving to the team.
Brad has over 15 years of experience in the Life Sciences industry globally, across government and private sectors. In Canada, he is recognized for his expertise in health outcomes, market access and policy strategy.
Prior to joining IQVIA (formerly IMS Brogan), he led the investment attraction function for Life Sciences at the Department of Foreign Affairs and International Trade, assisting global life science companies entering the Canadian market. Brad spent several years in the United States at a leading biotech strategy consulting firm, developing solutions in new product launch, marketing, sales, and business development for the global headquarters of top pharmaceutical and biotech companies, spanning key therapeutic areas such as Oncology and Immunology.
Brad is a Dean’s List graduate of the MBS program (integrated MSc Biotech + MBA ) at Keck Graduate Institute in Claremont, California, and holds a BSc in Physiology from McGill University. Brad speaks English and French, and is conversational in Mandarin Chinese.
Kimberly Robinson is Director, Pricing and Market Access at PDCI. Kimberly joined PDCI from PharmaKare Consulting, where she was Principal Consultant, with a focus on PMPRB pricing consultation. Prior to founding PharmaKare, Kimberly spent 18 years with Janssen. During her career at Janssen, she gained expertise in all aspects of market access, including HTA strategy development, health economics and outcomes research, government and stakeholder relations and strategic pricing.
Her longest role (2005 – 2012) was as Director, Strategic Pricing where she gained a diverse array of experience with PMPRB. This included taking 2 medicines to PMPRB Hearings, managing dozens of investigations, executing price increase strategies across dozens of DINs, contributing to the consultations leading to the 2010 Guidelines, and sitting on the Rx&D PMPRB Technical Working Group during the development of the DIP methodology and the revised CPI Guideline.
Kimberly has pricing and market access experience in a broad range of therapeutic areas, including: psychiatry, neurology, gastroenterology, endocrinology, rheumatology, oncology, Women’s Health and virology.
At PDCI, Kimberly leads the Pricing Team and focuses on the development and implementation of strategic public and private reimbursement strategies, market access assessments and new policy impact analyses and assessments.
Kimberly holds an undergraduate degree in Biology from Queen’s University, and MSc in epidemiology from Erasmus University in the Netherlands and an MBA from McGill. She is an avid supporter of the Canadian Association for Population Therapeutics (CAPT-ACTP) and currently serves as CAPT-ACTP Past President and Chair of the CAPT-ACTP Partnership Committee.
Alison Drinkwater joined Innomar Strategies as Senior Director, Strategic Consulting in 2016. She began her career in the fields of communication and marketing over 15 years ago, then moved to specialize in government relations, health economics and market access at Becton Dickinson and Baxter. Alison was the chair for the HTA (Health Technology Assessment) Committee for the MEDEC Association for 2 years, working to foster understanding of the differences between medical devices and pharmaceuticals through the payer lens.
Alison has experience in multiple therapeutic areas such as diabetes, oncology, diagnostics and hemophilia where she worked to examine how the clinical and economic impact of pharmaceuticals and diagnostics could remove market access barriers for patients and clinicians. Alison’s market access and health economics experience provides her with a solid foundation to evaluate and understand how the Canadian healthcare system can examine outcomes to ensure universal access and best practices around therapy. Today she oversees the consulting services offered by Innomar in the areas of strategic consulting, market access, health outcomes evidence generation and market research.
DOUGLASCLARK is Executive Director, with Patented Medicine Prices Review Board (PMPRB). A career public servant, Doug has a background in international trade law, intellectual property policy, pharmaceutical industry issues and competition law enforcement. Doug attended McGill University, the University of New Brunswick and l'Université de Moncton. He graduated law school in 1997 and was called to the Ontario Bar in 1999 after a clerkship with the Honourable Marc Noël of the Federal Court of Appeal. In2000, Doug was hired by Industry Canada to assist in the case management of two WTO-based legal challenges to Canada’s pharmaceutical patent regime brought by the US and EU. In 2006, Doug became the Director of the Patent and Trademark Policy Directorate at Industry Canada, where he led a number of legislative and regulatory initiatives under the Patent Act and Trademarks Act, including the development of Canada’s Access to Medicines Regime (CAMR) and pharmaceutical patent litigation reform. In 2009, Doug joined the Competition Bureau as Assistant Deputy Commissioner, Civil Matters Branch, where he was responsible for a number of high-profile prosecutions under the Competition Act. Doug became Executive Director of the PMPRB on October 28, 2013.
Helen Trifonopoulos is the Head of Health Policy and Patient Access at Novartis Oncology. She leads a team of professionals responsible for health economics and outcomes research, value and access strategy, government and stakeholder relations, and health systems partnerships.
Helen has over 20 years of experience in the pharmaceutical industry working for Merck and Novartis. She has held roles in commercial, medical education, policy and reimbursement across multiple therapeutic areas and various phases of the product life cycle. Most recently, Helen has had the privilege of working in novel areas like immuno-oncology and cell and gene therapies
Helen’s professional interests lie in exploring ways members of the healthcare ecosystem can work towards enhancing the life sciences in Canada and enabling patient access to innovative therapies while partnering for health system sustainability.
Helen holds a Bachelor of Arts in Political Science from McGill University and an MBA from the John Molson School of Business.
Joan is the director of health and disability policy for CLHIA (Canadian Life and Health Insurance Association), a voluntary trade association with member companies that account for 99 percent of Canada's life and health insurance business. In her role, Joan is responsible for analysis on industry issues, policy strategy development and to build consensus on concerns important to member companies. An important part of the health portfolio is working within industry, including with national healthcare associations as well as with provincial/federal payers on benefit programs, specifically on best practices, strategy, advocacy and sustainability.
Joan brings 20+ years of benefits management expertise to her position at CLHIA, having worked for insurers and administrators on both private and public sector programs, notably with First Canadian Health and Health Canada on the NIHB program and most recently with Medavie Blue Cross.
Joe leads Canada's innovative brand pharmaceutical industries efforts to support policies that enable the discovery, development and timely patient access of innovative medicines and vaccines that enhance the lives of all Canadians. He is responsible for the association’s policy work in the private market and public access through work with the pCPA and private market stakeholders. Joe is also very active on a number of research activities and other national files such as pharmacare and pricing policy. Part of my work to date includes numerous public presentation on these areas of responsibility.
As the National Practice Leader, Drug Benefits Solutions in Great-West Life’s Toronto Group Sales Office, Barbara Martinez supports sales offices across Canada on prescription drug management initiatives. She plays a key role in supporting advisors and their clients, including designing and managing drug benefit plans with Great-West Life Drug Solutions programs.
Barbara joined Great-West Life in 2012 after 10 years at Mercer, where she led the Canadian drug benefits consulting team. She’s a regular speaker at industry forums and a frequent commentator on employer drug programs. Her past experience also includes 13 years in the pharmaceutical industry, where she worked in sales and marketing as well as government and professional affairs.
Responsible for leading the formulary and programs area, including drug plan management activities, John Herbert directs Express Scripts Canada’s strategic initiatives and product development activities. John‘s powers of observation have helped him successfully lead Express Scripts Canada’s analytics activities, including the direction of financial and data analysis projects across the organization.
Prior to joining Express Scripts Canada in 1999, John gained valuable insight into the group insurance industry during his tenure as a consultant at London Life Insurance Company and as an employee benefits analyst at Morneau Shepell.
John graduated from the Richard Ivey School of Business at the University of Western Ontario with his Master of Business Administration in 1999.
Dr. Larry Lynd received his BSP in 1986 from the University of Saskatchewan and his PhD in the Department of Health Care and Epidemiology at UBC in 2002. He then completed a two-year post-doctoral fellowship in health economics with Dr. Bernie O'Brien at McMaster University. Currently, Dr. Lynd is associate dean, research; professor and director of the Collaboration for Outcomes Research and Evaluation (CORE) at the UBC Faculty of Pharmaceutical Sciences; scientist at the Centre for Clinical Epidemiology and Evaluation; scientist at the Centre for Health Evaluation and Outcomes Sciences; scholar at the Peter Wall Institute of Advanced Studies; and associate of the UBC School of Population and Public Health.
Dr. Lynd has made significant contributions serving on a number of committees, including chair of the Health Canada Special Advisory Committee on Non-Prescription Drugs, Special Advisory Committee to the Respiratory and Allergy Therapies Division of Health Canada, BC Ministry of Health Services Expensive Drugs for Rare Diseases Committee, and the BC PharmaNet Data Stewardship Committee.
Sang Mi Lee is a Senior Pharmacist at the pan-Canadian Pharmaceutical Alliance (pCPA) Office, supporting the Canadian provincial, territorial, and federal public drug programs to strengthen collaboration and achieve better value for brand and generic drugs. She is a leader in providing technical expertise as well as policy, clinical and analytical advice about drug funding recommendations and pan-Canadian drug negotiations to the Canadian public drug programs as well as other stakeholders. In her role, she also participates on various national advisory committees to support the mandate of the Office. Sang Mi previously worked for the Drug Programs Delivery Branch and the Policy/Strategy Branch of the Ontario Public Drug Programs, where she provided strategic advice in the development and implementation of drug funding policies, reimbursement criteria, and business processes.
Louis Thériault joined Innovative Medicines Canada in April 2018. Reporting to the President, he is responsible for the development of a comprehensive and forward-looking health policy strategy driven by evidence-based research. Louis is also focused on building and strengthening partnerships for effective policy implementation which enhance health systems performance and the competitiveness of the Canadian life science sector.
Louis has over 25 years of experience in economic research in the field of Public Policies. Before joining Innovative Medicines Canada, he held an executive role at the Conference Board of Canada leading a team of 40 researchers and professionals as the Vice President, Industry Strategy and Public Policy. Louis joined the Conference Board in 1997 and launched, managed, expanded and provided strategic direction for several lines of business including the Canadian Alliance for Sustainable Health Care (CASHC); the International Trade and Investment Centre; the Canadian Industrial Outlook Service; and the Metropolitan Outlook Service. Louis leveraged the quantitative analysis skills of the economic and forecast analysis team with the organizational performance and public policy expertise within the Conference Board to ensure success. Most recently, he launched the Board’s Health Economics Group, providing forward-looking, quantitative analysis of the sustainability of the Canadian healthcare system. Louis holds a Master’s Degree in Economics from Université Laval and is fluently bilingual.
Louis is recognized for his leadership, strategic thinking, initiative and organizational skills which positions him to add value in moving Canadian pharmaceutical policy issues forward on behalf of Innovative Medicines Canada’s members.
Sylvie Bouchard holds a bachelor’s degree in Pharmacy from Université Laval in Québec city (1988). She also has a diploma (1989) and a master’s degree (1992) in Hospital Pharmacy from Université Laval (Faculty of Pharmacy), and an MBA in Corporate Management (2001), also from Université Laval (Faculty of Business Administration).
Sylvie Bouchard was a hospital pharmacist and hospital pharmacy manager, first at the Centre hospitalier affilié universitaire de Québec (CHA), from 1988 to 2004, then at the Hôtel-Dieu de Québec, part of the Centre hospitalier universitaire de Québec (CHUQ), from 2006 to 2010. She has worked in several clinical departments and shown a strong interest in intensive care. In 2001, Ms. Bouchard introduced to the CHA new automation and distribution technologies for medications.
She joined the Conseil du médicament in April 2010, which became the Institut national d’excellence en santé et en services sociaux (INESSS) in 2011, where she has held various management positions over the years. Since April 2016, she has headed the Direction du médicament, a role involving the evaluation of medications for inclusion on the lists, the optimal use of drug products and collective prescriptions.
Kaitlyn Proulx is PDCI Market Access’ Managing Director and is responsible for managing the firm and leading the staff of twenty senior consultants and supporting staff. By offering full-service strategic pricing and market access consulting services, Kaitlyn and her team assist clients across all stages of product development.
Kaitlyn has led the development of numerous strategic PMPRB pricing assessments and submissions in a vast array of therapeutic areas and has successfully developed strategies to mitigate/minimize potential exposure during PMPRB investigational matters. She has also led the development successful formulary listing submissions to the CDR, INESSS, F/P/T drug plans, and private payer drug plans and has worked with clients in negotiating product listing agreements (PLAs) with pCPA, public payers (including Quebec) and private payers. She provides ongoing advice with respect to reimbursement strategy and PLA negotiations to help ensure timely listing on drug plan formularies. Kaitlyn maintains a strong working relationship with drug plan managers across Canada facilitating access to payers, decision makers and the latest information on drug plan policies and regulations.
Kaitlyn studied at the University of Ottawa and holds a Bachelor of Science with Honors in Biopharmaceutical Sciences and an option in Genomics. To compliment her science background, Kaitlyn has also taken a number of executive development courses through McGill University. Prior to joining PDCI in 2010, Kaitlyn worked at Health Canada within the Marketed Health Products Directorate in the Regulatory Advertising and Risk Communication Section where she was involved in the dissemination of post-approval risk communications concerning all regulated marketed health products.
John-Paul is Director, Reimbursement Strategy at PDCI. He brings more than 20 years of experience working in the health and pharmaceutical sectors. Prior to joining PDCI, John-Paul was Founder and Managing Director of Roubaix Strategies Inc.(RSI), and previously spent the better part of a decade in market access leadership roles, negotiating drug listing agreements for the reimbursement of innovative pharmaceuticals in Canada. His experience and knowledge in market access and negotiation strategy covers an extensive scope therapeutic and business areas, including strategic insights on how to obtain and maintain product reimbursement in both private and public drug plans.
John-Paul has led successful reimbursement strategies and negotiated funding agreements for conventional and specialty care products across Canada. He has worked with companies on successful strategies for the reimbursement of Drugs for Rare Diseases, Oncology and Biomarker Testing, Cardiovascular and Diabetes, Neuroscience, and Consumer Healthcare.
At PDCI, John-Paul leads the Reimbursement Strategy Team and focuses on the development and implementation of strategic public and private reimbursement strategies, market access assessments and new policy impact analyses and assessments.
John-Paul also brings with him the RSI Negotiations Strategy Programme. Combining many years of experience, this strategic programme delivers a tailored negotiation approach aimed at addressing the unique needs of our clients and preparing them for pCPA and other pricing and market access negotiations.
A sought-after speaker, strategist, and thought leader, John-Paul brings a keen understanding of the inter-relationships between public and private drug markets in Canada, having engaged extensively across both systems.
Prior to his career in the pharmaceutical industry, John-Paul worked work for several years with two major health professional associations in Ontario. This work included the successful negotiation of the first-ever agreement with the Ontario Government for compensation of pharmacies delivering influenza immunization clinics. He also spent several years working as an advisor in Federal and Ontario governments.
John-Paul holds a BA in Political Science from St. Jerome’s University (at Waterloo), and an Executive Certificate in Marketing Management from the Schulich School of Business. He is an active member of the Canadian Association for Healthcare Reimbursement, and BioteCanada (BTC), serving on BTC’s Health Advisory Board and Orphan Drug Working Group.
An avid cyclist and drummer, you may also be lucky enough to see John-Paul cycling to band rehearsal.
DURHANE WONG-RIEGER, PHD is President & CEO of the Canadian Organization for Rare Disorders (the umbrella organization of patients and patient groups) and chair of the Consumer Advocare Network (a national network for patient engagement in healthcare policy and advocacy). She is also President & CEO of the Institute for Optimizing Health Outcomes (providing training and direct service on health coaching and patient self-management) and Chair of the Canadian Heart Patient Network. Internationally, Durhane is Chair of Rare Disease International (the global alliance of rare disease patient organizations), Past-Chair of the International Alliance of Patient Organizations, member of the Editorial Board of The Patient- Patient Centred Outcomes Research, member of the Global Commission to End the Diagnosis Odyssey for Rare Diseases and member of Health Technology Assessment International Patient /Citizen Involvement Interest Group. She is a certified Health Coach and licensed T-Trainer with the Stanford-based Living A Healthy Life with Chronic Conditions.
Dr. Wong-Rieger has served on numerous health policy advisory committees and panels and is a member of the PMPRB Steering Committee on Modernization of Price Review Process Guidelines, Ontario’s Rare Disease Implementation Working Group, member of Genome Canada Steering Committee for the Rare Disease Precision Health Initiative and member of the Patient Liaison Forum for the Canadian Drugs and Technologies in Health.
Durhane has a PhD in psychology from McGill University and was professor at the University of Windsor, Canada from 1984-1999. She is married and has two children. She is a trainer and frequent lecturer and author of three books and many articles.
Pamela Fralick is an experienced leader who has been fostering positive change in Canada’s health sector for decades. Throughout her career, Ms. Fralick has distinguished herself in a variety of senior roles. A convener and innovator, Ms. Fralick is one of Canada’s leading, compassionate voices in the health sector. As the President of Innovative Medicines Canada, Ms. Fralick leads the industry association for Canada’s innovative pharmaceutical companies, working with its members and communities to ensure Canadians have access to the medicines they need, when they need them.
Prior to joining Innovative Medicines Canada, Ms. Fralick was President and CEO of the Canadian Cancer Society, Canada’s largest health charity, where she oversaw a three-year process of intense transformation, resulting in historic changes to the operational and governance structures of the organization.
Ms. Fralick previously served as president and CEO of the Canadian Healthcare Association (CHA) and as CEO of the Canadian Physiotherapy Association. At both Associations, Ms. Fralick led organizational initiatives designed to enhance sustainability and improve outcomes for the associations, their members and stakeholders. Ms. Fralick has also held senior positions with the Canadian Centre on Substance Abuse and Health Canada’s Alcohol and Other Drugs Unit.
True to her commitment to the health and well-being of Canadians, Ms. Fralick has served on numerous prestigious boards and collaboratives across Canada. She was Chair of the Health Action Lobby (HEAL) and Co-chair the Canadian Coalition for Public Health in the 21st Century (CCPH21). She has been active in many organizations as a senior volunteer, including the Centre for Addiction and Mental Health, the University of Ottawa Institute of Mental Health Research, Triathlon Canada and the International Triathlon Union. She is currently on the board of Outward Bound Canada (Chair) and the Canada Dance Festival (Past Chair).
Ms. Fralick has a BA in French and psychology and an MA in developmental psychology from Carleton University, as well as a Master of Public Administration (MPA) from Queen’s University. She also holds an ICD.D designation. She is trilingual – in English, French and German – and is an accomplished artist and athlete.
Jane is the Vice President, Strategic Partnerships, External Relations and Advocacy, BioScript Pharmacy Ltd. Jane’s extensive experience in both private and public sector healthcare environments provide her with unparalleled and unique insight into Canada’s healthcare system. An executive leader with expertise in business planning, health policy, government and stakeholder relations and operational management, Jane has worked in both community and hospital pharmacy, biotech and generic pharmaceutical manufacturing, drug wholesaling, corporate retail pharmacy and independent consulting. Currently Strategic Health Solutions Leader with BioScript Solutions, an integrated provider of specialty drug, clinical and infusion services offering an exceptional patient experience, customized and value-driven payer solutions and collaborative prescriber partnerships; Jane recently served as Chair of the Board of The Canadian Pharmacists Association. Jane holds a Bachelor of Science degree in Pharmacy from Dalhousie University and a Master of Business Administration from the University of Toronto as well as an Executive Fellowship from the Wharton School and Leonard Davis Institute of Health Economics, University of Pennsylvania. Jane holds numerous elected and appointed positions within healthcare associations across the country. She is Past Chair of the Board of the Ontario Pharmacists Association and is a past member of the Board of The Asthma Society of Canada. She served the Canadian Association of Hospital Pharmacists, the New Brunswick Pharmacists’ Association, the Ontario College of Pharmacists and the Canadian Generic Pharmaceutical Association in various board and committee roles and was a member of the Dalhousie College of Pharmacy Alumni Division executive. She has been a Certified Health Executive with the Canadian College of Health Service Executives and founded CO-Focus, a national symposium on pharmaceutical strategy. Jane is Past-Chair the Board of the Canadian Pharmacists Association. She was elected to the board in 2009, elected Vice President in 2011 and 2012, served as Chair from 2014-15 and has served on numerous board committees including Finance/Audit, Governance and Nominating, e-Business Review and Association Affairs. Jane is one of the founding mentors with the Leaders in Pharmacy program and was profiled in Pharmacy Business’ March, 2013 edition.
Ed Dybka was appointed to the role of General Manager at Ipsen Biopharmaceuticals Canada Inc. in October 2018. In this role, he is responsible for overseeing all of Ipsen’s operations across all therapeutic areas in Canada. Ed is a member of the Ipsen North America Leadership Team and the Ipsen Global Leadership Team.
Ed has a wealth of experience and has made a significant contribution to the Canadian Life Sciences industry with over 30 years in the pharmaceutical industry within the Canadian market. Prior to joining Ipsen Ed was the President & CEO of AstraZeneca Canada Inc., part of AstraZeneca PLC, one of the world’s leading biopharmaceutical companies.
In 2012, Ed led the Canadian establishment of Almirall, a start-up biopharmaceutical company focused on the treatment of respiratory diseases. Prior to establishing Almirall in Canada, Ed held a number of executive roles at GlaxoSmithKline Canada including Vice President of Marketing, Sales and Public Affairs & Reimbursement. During this time, he was accountable for the marketing and sales of all GSK pharmaceutical products, including specialty care, oncology and vaccines, achieving strong commercial performance and employee engagement.
In addition to his role at Ipsen, Ed is currently Vice-Chair of the board of Life Sciences Ontario and a Director on the board of Clinical Trials Ontario. He is also a member of the Health & Biosciences Economic Strategy Table for the Federal Ministry of Health and Ministry of Innovation, Science and Economic Development which recently published a set of foundational recommendations to accelerate the growth of the Health & Biosciences sector in Canada.
Philippe Lucas PhD(c) is Vice President, Global Patient Research & Access at Tilray, a federally authorized medical cannabis company based in Nanaimo, B.C., and a Graduate Researcher with the Canadian Institute for Substance Use Research. His scientific research includes the use of cannabis in the treatment of pain, mental health conditions and addiction.
Philippe is the founder of the Vancouver Island Compassion Society, and a former Victoria city councillor. He has received a number of accolades and awards for his work, including the Queen Elizabeth II Diamond Jubilee Medal for his research and advocacy on medical cannabis.
Marina Vasiliou is the Managing Director of Biogen Canada. In this role, Marina leads the Canadian affiliate for Biogen, one of the world’s leading biotechnology companies with a focus on innovated therapies for the treatment of neurological disorders. Prior to joining Biogen, Marina had an extensive career with Merck & Co Inc. in a variety of roles with responsibilities for sales, marketing and market access spanning numerous therapeutic and product areas in the US, EU and Middle East-Africa markets. Marina has been responsible for the marketing strategy and business development of products with hundreds of millions of dollars in annual revenue. She worked in France and across Europe as a sales and business director where she was responsible for the successful launch of new products. She has extensive experience with recruitment, coaching and management of high functioning teams and has been involved with the restructuring of national teams. Throughout her career, Marina has maintained her passion for focusing on patients and has developed an ability to understand the healthcare system in different countries and all its diverse stakeholders. As a leader, she combines her high energy with an understanding of how to manage across cultures. Originally from Cyprus, Marina holds a BSc in Marketing and Management from the University of Cyprus, a Masters in Sociology and Media Communication from the Ecole des Hautes Etudes en Sciences Sociales in Paris, France and an MBA from Penn State in the US. Since moving to Toronto in the Fall of 2017 with her family, Marina has been impressed by Canada and its multiculturalism and diversity. She looks forward to leading Biogen through a period of what promises to be one of exciting growth in the neurological area.
Alex MacKenzie is an attending pediatrician at the Children’s Hospital of Eastern Ontario (CHEO) in Ottawa, Canada and has served as the CEO and Science Director of the CHEO Research Institute as well as Vice President of Research for both CHEO and Canada’s federal genomic research funding agency, Genome Canada. In addition to being a founding scientist of the AeGera biotech company, Dr. MacKenzie’s laboratory has conducted translational research on the rare pediatric disorder spinal muscular atrophy over the past 25 years; in recent years it has broadened its focus through the enhanced Care for Rare project to search for therapies for a larger number of rare genetic diseases.
As a doctor trained at the Université de Sherbrooke and a specialist in public health, Dr. Luc Boileau holds a master’s in health administration from the Université de Montréal and a fellowship from the Canadian Health Services Research Foundation. In addition to his 25 years of clinical experience — particularly in emergency medicine — Luc has acquired solid experience in the management of health institutions and public health organizations, as well as the regional governance of health systems, while participating in and managing several regional and national projects. At the international level, he has also implemented and directed many study projects and missions, particularly in Africa. Between 1993 and 2001, Luc assumed the ministerial mandate of Director of Public Health, and between 2001 and 2008, the role of President and Director General of the Agence de la santé et des services sociaux de la Montérégie, a region of 1.4 million people located southwest of Montreal. In October 2008, the Government of Quebec appointed him as President and Chief Executive Officer of the Institut national de santé publique du Québec. In November 2013, the Conseil des Ministres announced the renewal of Luc’s appointment as President and Chief Executive Officer of the Institut national de santé publique du Québec. In January 2015, the Conseil des Ministres nominated Luc President and Chief Executive Officer of the Institut national d’excellence en santé et en services sociaux. Luc is one of two members representing Quebec on the CIHI board.
Scott Gavura is Director, Provincial Drug Reimbursement Programs at Cancer Care Ontario, and has held this role since 2007. In this position Scott is responsible for the strategic management of CCO’s cancer drug reimbursement programs as well as two non-drug patient access programs. Scott has been working for over 20 years to improve the use of medicines in roles ranging from front-line service as a community and hospital pharmacist to multiple roles in government and professional associations. Scott has a Bachelor of Science in Pharmacy degree and an MBA from the University of Toronto.
Prof. Michael Barry is a Consultant Clinical Pharmacologist and Head of the Department of Pharmacology & Therapeutics at the University of Dublin, Trinity College. He is the clinical director of the National Centre for Pharmacoeconomics (NCPE) which conducts pharmacoeconomic evaluations on medicines prior to reimbursement under the Community Drugs schemes in Ireland. He is Past-President (2010-2011) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He was a board member of the Health Information and Quality Authority (HIQA) and is a member of a number of National Committees on pricing and reimbursement of medicines. Prof. Barry chairs the New Drugs Committee and the Medication Safety Committee at St. James's Hospital, Dublin. In 2013 he was appointed as Clinical Lead for the new HSE Medicines Management Programme. He is a fellow of the Royal College of Physicians in Ireland and is a specialty trainer for Pharmacology & Therapeutics. His research areas include the cost-effectiveness of high cost drugs including chemotherapeutic agents and biologic drugs, pricing and reimbursement and performance based risk sharing schemes. He has published widely on the cost-effectiveness of medicines in the Irish healthcare setting.
Janet Yale is an accomplished leader and senior executive with long years of management experience in the private, public and not-for-profit sectors. Currently, she serves as the President and CEO of the Arthritis Society (Canada) after a long career in the telecommunications and broadcast sectors. In June 2018, she was appointed by the federal Ministers of Innovation, Science and Economic Development and Canadian Heritage to serve as Chair of The Broadcasting and Telecommunications Legislative Review Panel. Previously, she served as President and CEO of the Canadian Cable Television Association and, later, as the Executive Vice President at TELUS. Ms. Yale also served as a Director General at the CRTC and as General Counsel at the Consumers Association of Canada. Ms. Yale is Chair of the Arthritis Alliance of Canada, the out-going Chair of the Health Charities Coalition of Canada, Past-Chair of the Ontario Trillium Foundation and serves on the boards of Samara and the Ottawa Art Gallery. In 2008, she was awarded the United Way Community Builder Award for Volunteer of the Year. During the course of her distinguished career, she has received a number of awards and recognitions. In 2001, she was named “Woman of the Year” by the Canadian Women in Communications Organization. She is a recipient of both the Queen Elizabeth II Golden and Diamond Jubilee Medals. She was also named as one of Canada's 100 Most Powerful Women by the Women's Executive Network from 2004 to 2006, and inducted into the Hall of Fame in 2007. In 2005, she was named Businesswoman of the Year by the Women's Business Network and in 2006 she was named Woman Leader of the Year by Federated Press. A lawyer and economist by training, Ms. Yale is fully bilingual (English & French), a keen marathon runner and passionate about health, the arts and business. She splits her time between Ottawa and Toronto with her husband and grown children.
Ned Pojskic is Green Shield Canada’s Leader for Pharmacy and Health Provider Relations. In this role, he is responsible for setting GSC’s strategic direction with respect to provider and drug benefits management. He takes the lead in managing stakeholder relations with all health care providers, including pharmacy, dental, and paramedical. Ned is also responsible for overall drug formulary management, including pricing and policy as well as pharmaceutical industry partnerships.
With an industry background that includes a role as Director of Health Policy for the Ontario Pharmacists Association, Ned is a key member of GSC’s Strategic Market Solutions Team. Ned holds Masters and PhD degrees from the Department of Pharmaceutical Sciences at the University of Toronto and is currently appointed as an adjunct professor within the Leslie Dan Faculty of Pharmacy.
Kennet Brysting joined Gilead Sciences Canada, Inc., Gilead’s sixth largest business, as General Manager in January 2017. Kennet Brysting is a member of Gilead’s North America Senior Leadership Team and he is also a member of the Board of BIOTECanada. Kennet has over 20 years of global industry experience, including more than four years as the General Manager for Gilead Nordics (Sweden, Norway, Denmark, Finland and Iceland) – based in Stockholm, Sweden – which he grew to be one of Gilead’s top-10 markets. Previously, Kennet served as Vice President of Sales and Marketing at Pharmacosmos A/S, Denmark; General Manager of H. Lundbeck AB, Sweden, and various Finance & Commercial Director roles for Lundbeck in the United Kingdom, France and the Netherlands. Kennet Brysting is Danish, born and raised in Copenhagen and speaks English, French, Swedish and Danish. He has an EMBA from Cranfield University, UK, and a Bachelor’s Degree in Management Accounting from Copenhagen Business School.
Dylan Lamb-Palmer is a Manager of Pricing and Data Analytics at PDCI. Dylan joined PDCI full time in 2013 after several years as a summer student with PDCI.
Working with the PDCI’s Health Economics (HE) team and HE partners, Dylan develops health economic models (cost-utility, cost-effectiveness, and cost-consequence) and HE reports for submission to Canadian HTA agencies (CADTH CDR & pCODR, INESSS). The HE analyses use rigorous quantitative techniques (e.g., Markov modelling, network meta-analysis, Monte Carlo simulations) to assess the cost effectiveness of new drug products in their particular therapeutic context. The HE models may be prepared in the first instance for the Canadian market or by adapting a core HE model created for another market (often the UK) to the Canadian market.
Dylan leads the development of budget impact analysis (BIA) models for submission to public (federal / provincial) and private payers – these interactive Excel-based models are often the basis for negotiation product listing agreements with the pCPA and provincial drug plans.
Dylan is PDCI’s expert in assessing compliance with PMPRB’s CPI guideline and application of the “DIP” methodology. Dylan’s analytical skills have been instrumental in assessing historical sales and pricing data of patented medicines and identifying opportunities under the PMPRB guidelines for demonstrating price compliance and mitigating excess revenues. Dylan has led several training sessions for pharmaceutical clients on application of the PMPRB CPI Guidelines and “DIP” methodology.
Dylan leads PDCI’s drug claims analysis projects. PDCI maintains drug benefit claims databases for both public and private payers in Canada. These analyses are often important components of BIA and HE modelling as well as market share and longitudinal product switching projects.
Ashley Fraser is a Principal in the Life Sciences Practice of Charles River Associates. She has nine years of experience advising pharmaceutical, biotech, and medical device organizations. Her consulting experience includes pricing, reimbursement and market access strategies across the product development lifecycle, payer engagement, lifecycle management, and optimization of internal P&MA processes and team structures. Her engagements cover a range of therapeutic areas and emphasize Canada, US, and EU5 among other Global markets. Prior to her role at CRA, Ms. Fraser was an Associate Principal at QuintilesIMS.